Abstract:Context Hypoxia within the tumor microenvironment is a critical factor influencing the efficacy of immunotherapy, including immune checkpoint inhibition. Insufficient oxygen supply, characteristic of hypoxia, has been recognized as a central determinant in the progression of various cancers. The reemergence of evofosfamide, a hypoxia-activated prodrug, as a potential treatment strategy has sparked interest in addressing the role of hypoxia in immunotherapy response. This investigation sought to understand the kinetics and heterogeneity of tumor hypoxia and their implications in affecting responses to immunotherapeutic interventions with and without evofosfamide. Purpose This study aimed to investigate the influence of hypoxia on immune checkpoint inhibition, evofosfamide monotherapy, and their combination on colorectal cancer (CRC). Employing positron emission tomography (PET) imaging, we developed novel analytical methods to quantify and characterize tumor hypoxia severity and distribution. Procedures Murine CRC models were longitudinally imaged with [ 18 F]-fluoromisonidazole (FMISO)-PET to quantify tumor hypoxia during checkpoint blockade (anti-CTLA-4 + and anti-PD1 +/− evofosfamide). Metrics including maximum tumor [ 18 F]FMISO uptake (FMISOmax) and mean tumor [ 18 F]FMISO uptake (FMISOmean) were quantified and compared with normal muscle tissue (average muscle FMISO uptake (mAvg) and muscle standard deviation (mSD)). Histogram distributions were used to evaluate heterogeneity of tumor hypoxia. Findings Severe hypoxia significantly impeded immunotherapy effectiveness consistent with an immunosuppressive microenvironment. Hypoxia-specific PET imaging revealed a striking degree of spatial heterogeneity in tumor hypoxia, with some regions exhibiting significantly more severe hypoxia than others. The study identified FMISOmax as a robust predictor of immunotherapy response, emphasizing the impact of localized severe hypoxia on tumor volume control during therapy. Interestingly, evofosfamide did not directly reduce hypoxia but markedly improved the response to immunotherapy, uncovering an alternative mechanism for its efficacy. Conclusions These results enhance our comprehension of the interplay between hypoxia and immune checkpoint inhibition within the tumor microenvironment, offering crucial insights for the development of personalized cancer treatment strategies. Non-invasive hypoxia quantification through molecular imaging evaluating hypoxia severity may be an effective tool in guiding treatment planning, predicting therapy response, and ultimately improving patient outcomes across diverse cancer types and tumor microenvironments. It sets the stage for the translation of these findings into clinical practice, facilitating the optimization of immunotherapy regimens by addressing tumor hypoxia and thereby enhancing the efficacy of cancer treatments.

Flux phases in polarized spin liquids.

Predicting Response to Radiotherapy in Tumors with PET/CT: when and How?

Positron Emission Tomography Imaging of Tumor Hypoxia

Positron Emission Tomography Imaging Sheds New Light on Hypoxia and Antitumor Therapies

Is there a role for [18F]-FMISO PET to guide dose adaptive radiotherapy in head and neck cancer? A review of the literature

Quantitative hypoxia imaging for treatment planning of radiotherapy

Imaging of Tumor Hypoxia With Radionuclide-Labeled Tracers for PET

[Differential diagnosis between systemic degenerative neurologic syndromes and cervical spine-spinal cord pathology].

Impact of Hypoxia on Radiation-Based Therapies for Liver Cancer

PET Hypoxia Imaging and Progress of Enhancing Radio-Sensitivity in Hypoxic Tumor

Prognostic significance of pretreatment PET parameters in inoperable, node-positive NSCLC patients with poor prognostic factors undergoing hypofractionated radiotherapy: a single-institution retrospective study

The potential of targeted radionuclide therapy to treat hypoxic tumor cells

Advances in PET and MRI imaging of tumor hypoxia

Hypoxia Predicts Favorable Response to Carbon Ion Radiotherapy in Non-Small Cell Lung Cancer (NSCLC) Defined by 18F-FMISO Positron Emission Tomography/computed Tomography (PET/CT) Imaging

Abstract 5979: Evaluating therapeutic strategies against lung cancer using multispectral optoacoustic tomography

Alternative and New Radiopharmaceutical Agents for Lung Cancer

Prognostic value of tumour blood flow, [18F]EF5 and [18F]FDG PET/CT imaging in patients with head and neck cancer treated with radiochemotherapy

The lung cancers: staging and response, CT, 18F-FDG PET/CT, MRI, DWI: review and new perspectives

[ 18 F]FMISO-PET imaging reveals the role of hypoxia severity in checkpoint blockade response

Positron Emission Tomography-Based Short-Term Efficacy Evaluation and Prediction in Patients With Non-Small Cell Lung Cancer Treated With Hypo-Fractionated Radiotherapy

Radiotherapy boost in patients with hypoxic lesions identified by 18F-FMISO PET/CT in non-small-cell lung carcinoma: can we expect a better survival outcome without toxicity? [RTEP5 long-term follow-up]